Upcoming Webinar
repotrectinib (Augtyro®) in Patients with ROS1 Fusion-Positive NSCLC: Data from the Pivotal Phase 1/2 TRIDENT-1 Trial
Date: November 13, 2025 | 2:00 PM
When: Thursday, November 13 | 2 p.m. EST
Presenters: Whitney Lewis, PharmD, BCOP | Bristol Myers Squibbs
Repotrectinib (Augtyro®) is offering new possibilities for patients with ROS1 fusion–positive NSCLC.
In this session, Whitney Lewis, PharmD, BCOP (Bristol Myers Squibb) will review data from the pivotal TRIDENT-1 trial and what it means for treatment decisions in real-world practice.
We’ll talk about:
- How repotrectinib performs in treatment-naïve vs. pretreated patients
- What the data show about CNS activity and resistance management
- How its safety and efficacy compare to other ROS1-targeted therapies
- Key factors to consider for sequencing and patient selection
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
Additional Upcoming Webinars
Upcoming Webinar
Precision Medicine in Breast Cancer – A Collaborative Approach
November 10, 2025 | 2:00 PM
November 12, 2025 | 2:00 PM
Upcoming Webinar
Techs Talk Access, Safety, and Growth in Oncology Pharmacy
November 12, 2025 | 3:00 PM







